Engraftment in the tissues after tail vein injections: human cells detected by real-time PCR for human Alu sequences
. | Weeks after injection . | Brain section . | . | . | . | . | . | . | . | . | . | . | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mouse no. . | . | A . | B . | C . | D . | E . | BM . | Heart . | Liver . | Kidney . | Spleen . | Lung . | ||||
| 1 | 1 | ND | 180 ± 9.8 | 246 ± 24.0 | 157 ± 26.7 | 1 562 ± 56.2* | ND | 377 ± 57.2 | ND | 3781 ± 45.3 | 2225 ± 121.2* | 5656 ± 85.2 | ||||
| 2 | 1 | ND | 88 ± 12.3 | ND | ND | ND | + | ND | ND | 235 ± 58.2 | ND | 1756 ± 45.6 | ||||
| 3 | 3 | 4044 ± 54.3* | ND | ND | 480 ± 41.6† | ND | + | 380 ± 24.5 | ND | ND | 3715 ± 81.9* | ND | ||||
| 4 | 3 | ND | 130 ± 59.8 | ND | 113 ± 2.3 | ND | + | 1882 ± 14.2* | 15 246 ± 75.6 | ND | ND | 1110 ± 75.6 | ||||
| 5 | 3 | ND | ND | ND | 545 ± 98.3‡ | 265 ± 45.3 | ND | 364 ± 9.2 | ND | ND | 1466 ± 67.3 | ND | ||||
| 6 | 3 | ND | ND | ND | ND | 75 086 ± 98.6* | + | 320 ± 13.9 | ND | ND | 1427 ± 8.9 | 1130 ± 56.8 | ||||
| 7 | 5 | ND | ND | 1096 ± 84.2 | 248 ± 45.3 | ND | ND | 924 ± 51.0 | ND | ND | 1954 ± 54.8 | ND | ||||
| 8 | 5 | ND | 297 ± 26.3* | ND | 530 ± 49.6* | 780 ± 87.6 | ND | 372 ± 5.6 | ND | ND | ND | 1300 ± 46.9* | ||||
. | Weeks after injection . | Brain section . | . | . | . | . | . | . | . | . | . | . | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mouse no. . | . | A . | B . | C . | D . | E . | BM . | Heart . | Liver . | Kidney . | Spleen . | Lung . | ||||
| 1 | 1 | ND | 180 ± 9.8 | 246 ± 24.0 | 157 ± 26.7 | 1 562 ± 56.2* | ND | 377 ± 57.2 | ND | 3781 ± 45.3 | 2225 ± 121.2* | 5656 ± 85.2 | ||||
| 2 | 1 | ND | 88 ± 12.3 | ND | ND | ND | + | ND | ND | 235 ± 58.2 | ND | 1756 ± 45.6 | ||||
| 3 | 3 | 4044 ± 54.3* | ND | ND | 480 ± 41.6† | ND | + | 380 ± 24.5 | ND | ND | 3715 ± 81.9* | ND | ||||
| 4 | 3 | ND | 130 ± 59.8 | ND | 113 ± 2.3 | ND | + | 1882 ± 14.2* | 15 246 ± 75.6 | ND | ND | 1110 ± 75.6 | ||||
| 5 | 3 | ND | ND | ND | 545 ± 98.3‡ | 265 ± 45.3 | ND | 364 ± 9.2 | ND | ND | 1466 ± 67.3 | ND | ||||
| 6 | 3 | ND | ND | ND | ND | 75 086 ± 98.6* | + | 320 ± 13.9 | ND | ND | 1427 ± 8.9 | 1130 ± 56.8 | ||||
| 7 | 5 | ND | ND | 1096 ± 84.2 | 248 ± 45.3 | ND | ND | 924 ± 51.0 | ND | ND | 1954 ± 54.8 | ND | ||||
| 8 | 5 | ND | 297 ± 26.3* | ND | 530 ± 49.6* | 780 ± 87.6 | ND | 372 ± 5.6 | ND | ND | ND | 1300 ± 46.9* | ||||
Real-time PCR assays for human Alu sequences are expressed as number of human cells per organ. Ratios of RS-MSCs to SR-MSCs as assayed by the competitive SNP assay are presented in the symbolled footnotes. Values indicate the average number of human MSCs ± SD. See Figure S4A for expression of data as percent of infused MSCs.
A indicates olfactory bulb; B, olfactory cortex; C, striatum; D, hippocampus; E, cerebellum; ND, not detected with assay sensitivity to 1 human cell per 2 × 105 mouse cells; +, Alu sequences detected.
Ratio of RS-MSCs to SR-MSCs by SNP assay greater than 1000:1
Ratio of RS-MSCs to SR-MSCs by SNP assay 10:1
Ratio of RS-MSCs to SR-MSCs by SNP assay less than 1:1000